Polycyanoacrylate nanoparticles

Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, Gomis JM, Appel M, d Angelo J, Couvreur P (1999) Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 60 121-128. 

Calvo, P., et al. 2001. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug... 

Kreuter, J., U. Muller, et al. (1989). Quantitative and microaudiographic study on mouse intestinal distribution of polycyanoacrylate nanoparticles. Int J Pharm 55 39-45. 

Calvo P, Gouridn B, Chacun H, Desmaele D, D Angelo J, Noel J, Georgin D, Fattal E, Andreux J, Couvreur P (2001) Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug canier for brain delivery. Pharm Res 18 1157—1166. 

Calvo P, Gouritin B, Villarroya H, Eclancher F, Giannavola C, Klein C, Andreux JP, Couvreur P (2002) Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci 15 1317-1326. 

PEG-coated (polycyanoacrylate) nanoparticles Paclitaxel Transferrin S-180 bearing mice ... 

M.T. Peracchia, S. Harnisch, H. Pinto-Alphandary, A. Gulik, J.-C. Dedieu, D. Desmaele, J. dAngelo, R.-H. Muller, and P. Couvreur, Visualization of in vitro protein-rejecting properties of PEGylated Stealth polycyanoacrylate nanoparticles. Biomaterials, 20 (14), 1269-1275,1999. 

M.T. Peracchia, E. Fattal, D. Desmaele, M. Besnard, J.P. Noel, J.M. Gomis, M. Appel, J. dAngelo, and P. Couvreur, Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. Journal of Controlled Release, 60 (1), 121-128,1999. 

P. Calvo, B. Gouritin, 1. Brigger, C. Lasmezas, J.P Deslys, A. Williams, J.P Andreux, D. Dormont, and P Couvreur, PEGylated polycyanoacrylate nanoparticles as vector for drug deUvery in prion diseases. Journal of Neuroscience Methods, 111 (2), 151-155,2001. 

Peracchia, M.T., Hamisch, S., Pinto-Alphandary, H., Gulik, A., Dedien, J.C., Desmaele, D., d Angelo, J., Muller, R.H. and Couvreur, P. (1999) Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomater. 20,1269-1275. 

Calvo P, et al. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. 

Preparation of nanoparticles can be by a variety of different ways. The most important and frequently used is emulsion polymerization others include interfacial polymerization, solvent evaporation, and desolvation of natural proteins. The materials used to prepare nanoparticles are also numerous, but most commonly they are polymers such as poly-alklcyanoacrylate, polymethylmethacrylate, poly-butylcyanoacrylate, or are albumin or gelatin. Distribution patterns of the particles in the body can vary depending on their size, composition, and surface charge [83-85]. In particular, nanoparticles of polycyanoacrylate have been found to accumulate in certain tumors [86,87]. 

Spray drying has been proposed as a means of providing a carrier for efficient nanoparticle delivery (Fig. 26). A nanoparticle suspension was spray dried in the presence of lactose, used as a carrier, to demonstrate that nanoparticles remained in the nano-range size after spray drying and provide a means to improve their delivery by inhalation (73). Nanoparticles made out of polystyrene, colloidal silica (20) as well as gelatin and polycyanoacrylate (73) have been spray dried in the presence of lactose DPPC or DMP to improve their drug delivery efficiency. 

ODNs directed to a point mutation in codon 12 of the HA-ras mRNA adsorbed to such nanoparticles were injected into tumor tissue, and suppressed oncogene-mediated tumor proliferation at concentrations 100 times lower than the free oligonucleotides [435], Because of the negative surface potential ( -potential) of polycyanoacrylate particles, a cationic copolymer such as DEAE-dextran (known as a transfection enhancer), or a hydrophobic cationic detergent such as CTAB, are usually used. In the meantime, base-modified nanoparticles of the methacrylate type have also been described [399-401, 404, 405, 407]. They have shown to increase plasma stability of ODNs and increase cellular uptake. Effects of toxicity were observed depending on the type of modification. As they are also used as car-... 

Long-circulating PECylated polycyanoacrylate (PEC-PHDCA) nanoparticles Drug carrier for brain delivery and has been shown to modify the permeability of the BBB 1831... 

---